KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $127.0 million.

  • Eli Lilly's Gains from Investment Securities fell 1639.24% to $127.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $645.0 million, marking a year-over-year decrease of 472.67%. This contributed to the annual value of $645.0 million for FY2025, which is 472.67% down from last year.
  • As of Q4 2025, Eli Lilly's Gains from Investment Securities stood at $127.0 million, which was down 1639.24% from $150.1 million recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Gains from Investment Securities registered a high of $971.9 million during Q3 2023, and its lowest value of -$643.1 million during Q2 2023.
  • Its 5-year average for Gains from Investment Securities is $179.2 million, with a median of $139.7 million in 2022.
  • Per our database at Business Quant, Eli Lilly's Gains from Investment Securities skyrocketed by 53606.56% in 2021 and then plummeted by 64500.0% in 2023.
  • Eli Lilly's Gains from Investment Securities (Quarter) stood at $927.2 million in 2021, then crashed by 86.4% to $126.1 million in 2022, then skyrocketed by 103.17% to $256.2 million in 2023, then plummeted by 40.71% to $151.9 million in 2024, then dropped by 16.39% to $127.0 million in 2025.
  • Its Gains from Investment Securities stands at $127.0 million for Q4 2025, versus $150.1 million for Q3 2025 and $171.2 million for Q2 2025.